Marshall Wace North America L.P. bought a new position in Thermo Fisher Scientific Inc (NYSE:TMO) during the first quarter, Holdings Channel reports. The fund bought 231,025 shares of the medical research company’s stock, valued at approximately $35,578,000.

A number of other hedge funds also recently added to or reduced their stakes in TMO. Independent Portfolio Consultants Inc. boosted its stake in Thermo Fisher Scientific by 0.3% in the first quarter. Independent Portfolio Consultants Inc. now owns 730 shares of the medical research company’s stock worth $112,000 after buying an additional 2 shares during the period. Sharkey Howes & Javer boosted its stake in Thermo Fisher Scientific by 1.0% in the first quarter. Sharkey Howes & Javer now owns 733 shares of the medical research company’s stock worth $113,000 after buying an additional 7 shares during the period. Penserra Capital Management LLC boosted its stake in Thermo Fisher Scientific by 9.5% in the first quarter. Penserra Capital Management LLC now owns 1,150 shares of the medical research company’s stock worth $176,000 after buying an additional 100 shares during the period. South Texas Money Management Ltd. bought a new stake in Thermo Fisher Scientific during the first quarter worth approximately $202,000. Finally, Fairfax Financial Holdings Ltd Can bought a new stake in Thermo Fisher Scientific during the first quarter worth approximately $206,000. Institutional investors own 87.15% of the company’s stock.

Thermo Fisher Scientific Inc (NYSE:TMO) traded down 0.16% during trading on Monday, hitting $176.05. 25,638 shares of the stock traded hands. Thermo Fisher Scientific Inc has a 12 month low of $139.07 and a 12 month high of $182.87. The firm’s 50-day moving average is $176.88 and its 200-day moving average is $164.14. The stock has a market cap of $68.66 billion, a P/E ratio of 30.67 and a beta of 1.06.

Thermo Fisher Scientific (NYSE:TMO) last posted its quarterly earnings data on Wednesday, July 26th. The medical research company reported $2.30 earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of $2.27 by $0.03. The business had revenue of $5 billion during the quarter, compared to the consensus estimate of $4.92 billion. Thermo Fisher Scientific had a return on equity of 15.97% and a net margin of 11.80%. The company’s revenue was up 10.2% compared to the same quarter last year. During the same period in the prior year, the company earned $2.03 earnings per share. On average, analysts forecast that Thermo Fisher Scientific Inc will post $9.24 EPS for the current year.

The company also recently disclosed a quarterly dividend, which will be paid on Monday, October 16th. Stockholders of record on Friday, September 15th will be issued a $0.15 dividend. This represents a $0.60 annualized dividend and a dividend yield of 0.34%. The ex-dividend date is Thursday, September 14th. Thermo Fisher Scientific’s payout ratio is currently 10.45%.

ILLEGAL ACTIVITY WARNING: “Marshall Wace North America L.P. Takes Position in Thermo Fisher Scientific Inc (NYSE:TMO)” was first published by Daily Political and is the property of of Daily Political. If you are accessing this story on another site, it was copied illegally and republished in violation of US & international trademark & copyright law. The correct version of this story can be read at https://www.dailypolitical.com/2017/08/07/marshall-wace-north-america-l-p-takes-position-in-thermo-fisher-scientific-inc-nysetmo.html.

TMO has been the subject of a number of recent analyst reports. Deutsche Bank AG lifted their target price on shares of Thermo Fisher Scientific from $163.00 to $188.00 and gave the stock a “buy” rating in a research note on Friday, April 28th. BTIG Research lifted their target price on shares of Thermo Fisher Scientific from $180.00 to $190.00 and gave the stock a “buy” rating in a research note on Friday, April 28th. Barclays PLC set a $175.00 target price on shares of Thermo Fisher Scientific and gave the stock a “buy” rating in a research note on Wednesday, April 26th. Leerink Swann set a $187.00 target price on shares of Thermo Fisher Scientific and gave the stock a “buy” rating in a research note on Thursday, April 27th. Finally, Bank of America Corporation lifted their target price on shares of Thermo Fisher Scientific from $190.00 to $200.00 and gave the stock a “buy” rating in a research note on Tuesday, May 9th. One research analyst has rated the stock with a hold rating, sixteen have given a buy rating and one has given a strong buy rating to the stock. The stock currently has a consensus rating of “Buy” and an average price target of $188.56.

In related news, CEO Marc N. Casper sold 20,000 shares of the stock in a transaction on Thursday, June 1st. The stock was sold at an average price of $172.79, for a total transaction of $3,455,800.00. Following the completion of the sale, the chief executive officer now directly owns 269,279 shares of the company’s stock, valued at $46,528,718.41. The sale was disclosed in a filing with the SEC, which is available through the SEC website. Also, CFO Stephen Williamson sold 2,500 shares of the stock in a transaction on Monday, June 5th. The stock was sold at an average price of $176.26, for a total value of $440,650.00. Following the sale, the chief financial officer now directly owns 37,790 shares of the company’s stock, valued at $6,660,865.40. The disclosure for this sale can be found here. Insiders sold 27,188 shares of company stock valued at $4,702,223 over the last three months. Corporate insiders own 0.49% of the company’s stock.

About Thermo Fisher Scientific

Thermo Fisher Scientific Inc develops, manufactures and sells a range of products. The Company provides analytical instruments, equipment, reagents and consumables, software and services for research, manufacturing, analysis, discovery and diagnostics. It operates through four segments: Life Sciences Solutions, Analytical Instruments, Specialty Diagnostics, and Laboratory Products and Services.

Want to see what other hedge funds are holding TMO? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Thermo Fisher Scientific Inc (NYSE:TMO).

Institutional Ownership by Quarter for Thermo Fisher Scientific (NYSE:TMO)

Receive News & Ratings for Thermo Fisher Scientific Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Thermo Fisher Scientific Inc and related companies with MarketBeat.com's FREE daily email newsletter.